Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment

Next Previous
Trial Profile

AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Beludavimab (Primary) ; Favipiravir (Primary) ; Molnupiravir (Primary) ; Nirmatrelvir+ritonavir (Primary) ; Nitazoxanide (Primary) ; Nomacopan (Primary) ; Sotrovimab (Primary)
  • Indications COVID-19 respiratory infection
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms AGILE; AGILE CST-2; AGILE CST-3A; AGILE CST-5; AGILE CST-8
  • Sponsors GSK

    • Most Recent Events

    • 06 Mar 2024 Results(AGILE CST5, n=24 ) presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
    • 06 Mar 2024 Results presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
    • 05 Jan 2024 Recruitment End Date is 30/05/2025, according to ISRCTN: Current Controlled Trials
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top